Publication | Open Access

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Selective InhibitionHematological MalignancyOncologyMedicinePharmacotherapyAnti-cancer AgentPharmacologyRadiation OncologyMyeloid Neoplasia